Patent ID: 11932877
Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Field: Measurement (Instruments)
Classification: CPC C  A  G | IPC C  G

Claim 0:
1. A method for drug screening for treating a patient suffering from human fibrolamellar hepatocellular carcinoma (hFL-HCC), comprising culturing hFL-HCC cells in a serum-free medium to form organoids, introducing a candidate drug to the hFL-HCC in the form of organoids measuring expression of at least one of C1Oorf128, CA12, CREB3L1, GALNTL6, IRF4, ITPRIP, KCNE4, NOVA1, OAT, PAK3, PCSK1, PHACTR2, RPS6KA2, SLC16A14, TMEM163, or TNRC6C in the organoids treated with the candidate drug, and selecting the candidate drug that causes reduced expression of at least one of C1Oorf128, CA12, CREB3L1, GALNTL6, IRF4, ITPRIP, KCNE4, NOVA1, OAT, PAK3, PCSK1, PHACTR2, RPS6KA2, SLC16A14, or TMEM163.